Pharmaceutical giant Eli Lilly plans to establish four new drug manufacturing facilities in the U.S., company officials announced.
The $27 billion initiative is expected to create about 3,000 permanent positions and some 10,000 construction jobs.
Active Ingredients and Injectables
The company has not announced specific locations for the facilities, although it indicates that it expects to produce medicines in them within five years. Three sites will make active ingredients for drugs, while the fourth will produce sterile injectable medications.
$50B in Total U.S. Investments
Lilly officials noted that it invested $23 billion in its U.S. operations in the preceding five years, including expansions in its native Indiana and new plants in North Carolina and Wisconsin.
Bolstering Domestic Manufacturing
The Wall Street Journal noted that the announcement comes amid uncertainty in the pharmaceutical industry’s global supply chain following potential tariffs from the Trump administration.
The U.S., Ireland, Switzerland, and other countries supply large shares of the world’s drugs, while China and India are key sources of active ingredients and generic drugs, respectively.
The Journal also highlighted a push from Lilly and other pharmaceutical companies to extend the corporate tax cuts passed in 2017.
Image credit: Tada Images/Shutterstock
